Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer

Title	Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer
Authors	I‐Wei Ho, Yi-Ru Tseng and Chun-Yu Liu et al.
Magazine	Journal of Cancer
Date	02/11/2025
DOI	10.7150/jca.105199
Introduction	Rapid advancements in therapeutics have improved breast cancer treatment, yet challenges persist, particularly in advanced stages. Vinorelbine, a semisynthetic vinca alkaloid, is effective and well tolerated for breast cancer. The vinorelbine and platinum combination is an underreported regimen with good tolerance. Bevacizumab, a VEGF-neutralising antibody, has shown efficacy in HER2-negative metastatic breast cancer when paired with chemotherapy. This study investigates the clinical and molecular effects of vinorelbine-platinum in heavily pretreated HER2-negative metastatic breast cancer, and the added impact of bevacizumab. A retrospective study was conducted at Taipei Veterans General Hospital, evaluating the effectiveness of vinorelbine-platinum in heavily pretreated HER2-negative metastatic breast cancer patients from 2016 to 2020, with some receiving additional bevacizumab. Transcriptional profiling was performed on a triple-negative breast cancer cell line treated with cisplatin-vinorelbine using RNA sequencing. The cohort included 54 patients, 50% of whom received ≥ 5 lines of systemic treatment in the metastatic setting. All patients had received anthracyclines and taxane. For those treated with vinorelbine-platinum, the median progression-free survival (PFS) and overall survival (OS) were 2.3 and 7.3 months, respectively. With bevacizumab, median PFS improved to 4.1 months. Objective response rate (ORR) and disease control rate (DCR) without bevacizumab were 11.1% and 27.7%, respectively, improving to 25% and 83.3% with bevacizumab. Adverse events occurred in 37.0% of patients, with no grade IV events reported. Transcriptional profiling revealed significant downregulation of MAPK pathway, angiogenesis, and growth factor signalling related genes. The vinorelbine-platinum regimen, particularly with bevacizumab, shows potential efficacy even in heavily pretreated HER2-negative metastatic breast cancer patients. Molecular analyses of treated cells highlight potential targets and mechanisms of action, providing a basis for future therapeutic strategies.
Quote	I‐Wei Ho, Yi-Ru Tseng and Chun-Yu Liu et al. Addition of Bevacizumab to Vinorelbine-Platinum combination is effective in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. 2025. DOI: 10.7150/jca.105199
Element	Platinum (Pt)
Industry	Pharmaceutical Industry